1.240USD-1.59%Mkt Cap: 4.99M USDP/E: —Last update: 2026-05-26
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, incl…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap4.99M USD
Enterprise Value-1.96M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.56M USD
Revenue/Share—
Last Price1.240 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.32
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.53
EPS (TTM)-4.17
EPS (Forward)-3.87
52W Range
1.1002% of range8.000
52W High8.000 USD
52W Low1.100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-121.45%
ROA-96.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.76M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-127.16%
Net Debt-6.95M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio7.09
Quick Ratio6.60
Book Value/Sh2.340 USD
Cash/Share1.727 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateAug 1, 2025
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)4.000 USD
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.4.02M
Float3.17M
Insiders24.82%
Institutions7.37%
Short Interest
Short Ratio1.7d
Short % Float4.80%
Short % Out.3.76%
Shares Short151.10K
Short (prev mo.)264.04K
Technical
SMA 501.277 (-2.9%)
SMA 2002.878 (-56.9%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)64.14K
Avg Vol (10d)46.10K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—